Kaspar van den Dries, Ph.D.
Science & Innovation Sr. Director, Softgels, Pharma Services
Tilburg, Netherlands
Key roles and responsibilities
- Head of research and development for the softgels business unit at Thermo Fisher Scientific, leading the development teams at the High Point, NC and Tilburg sites
- Help clients choose and develop the right dosage forms and technologies to meet their goals from development through commercial manufacturing
- Provide leadership to technical teams at early development site in Milton Park, U.K. and late stage development site in Bourgoin, France
Professional highlights
- Co-founder and Chief Scientific Officer of Brammer Bio, which was acquired by Thermo Fisher Scientific in 2019
- Formerly an associate professor of molecular genetics and microbiology as well as director of biotherapeutic programs at the University of Florida, and assistant professor of pediatrics at Harvard Medical School
- Experience in viral vector industry spans over thirty-three years; previously employed by Cell Cenesys, Somatix, Merlin, and Avigen
- Engaged in the development of gene transfer vector and vaccine technology along with therapeutic applications
- Author of over seventy scientific publications and also eight U.S. patents
Education
- Doctor of Philosophy and Master’s degree in pharmaceutical sciences from the University of Utrecht, NL
Scientific expertise
- Formulation & process development
- Solid dose formulation (tablets, capsules, and softgels)
- Late stage process development projects
- Technology transfer
- Regulatory filings
- Solubility enhancement
- Biopharmaceuticals
- Lipid-based formulations
- Quality by design
- Risk assessment and experimental designs
- Process analytical technologies (NIR)
- In vitro – in vivo relationships
